Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States

Abstract

Background: Clinical trials have established calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam as a well-tolerated and efficacious topical therapy for psoriasis.

Methods: A chart review of 24 US healthcare providers gathered real-world information (clinical characteristics and outcomes, safety, and resource utilization) for patients (≥18 years old) prescribed Cal/BD foam between January 1 and October 31, 2016, along with healthcare provider characteristics and perceptions of Cal/BD foam.

Results: Data were reported from 105 patients and 177 active psoriatic lesions. Cal/BD foam was applied once-daily; the prescription was 4 weeks for 69/177 (39%) lesions (median 4, range 1–26 weeks). Knees (n = 41; 23%) and elbows (n = 37; 20%) were the most frequently treated areas. Among 114 lesions, severity improved from “mild”/“moderate”/“severe” to “clear”/“almost clear” in 71%, and 54% had a clinically significant improvement (two-step/greater improvement) in lesion severity from baseline. Of 128 lesions with baseline itch, 90% were not itchy at the best treatment response. Most healthcare providers reported prescribing Cal/BD foam because of its overall efficacy (n = 20/23; 87%). Adverse events were reported in 1/105 patients (1%).

Conclusion: Data from real clinical practice demonstrate that Cal/BD foam improves psoriasis disease severity and associated itch in patients and further extend results of clinical trials.

Keywords:

• Calcipotriene
• betamethasone dipropionate
• foam
• real-world
• psoriasis
• itch

Disclosure statement

J.J.W is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis; a consultant for AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Dermira, Dr. Reddy’s Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Promius Pharma, Regeneron, Sun Pharmaceutical, and UCB, Valeant Pharmaceuticals North America LLC; and a speaker for AbbVie, Celgene, Novartis, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC. A.W.A. has served as an investigator, advisor, and/or consultant to AbbVie, Janssen, Novartis, Lilly, Regeneron, Sanofi, Leo, Science 37, Modernizing Medicine, and Ortho Dermatologics. K.A.V. and M.L. are employees of LEO Pharma Inc.

Additional information

Funding

This study was sponsored by LEO Pharma Research Foundation. Medical writing support was provided by Andrew Jones, Ph.D., from Mudskipper Business Ltd, funded by LEO Pharma Inc.